AbbVie reported 10.2% top-line growth and 22.9% adjusted diluted EPS growth in the second quarter. Management raised 2026 revenue guidance by $300 million to $67.6 billion but slightly lowered its adjusted diluted EPS guidance range to $13.87-$14.07 due to the pending Apogee acquisition.
AbbVie's next-generation immunology drugs targeting the IL-23 (Skyrizi) and JAK (Rinvoq) pathways are mitigating biosimilar headwinds to older blockbuster Humira.
AbbVie has had to depend on acquisitions to boost its late-stage pipeline, suggesting less successful internal research and development activities.
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.03 | 40.22 | 42.36 |
Price/Book Value | — | 31.13 | 8.00 |
Price/Sales | 6.90 | 13.32 | 5.07 |
Price/Cash Flow | 19.00 | 32.26 | 15.22 |
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.49 | 0.68 | 0.71 |
Current Ratio | 0.81 | 1.35 | 1.32 |
Interest Coverage | 3.89 | — | 4.28 |
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 14.29% | 24.05% | 6.27% |
Return on Equity (Normalized) | — | 105.62% | 16.68% |
Return on Invested Capital (Normalized) | 32.02% | 39.55% | 9.82% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|@NPPC@w | LOCK|!?J | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|m&X>#jC | LOCK|gw^ | $632B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|#&HVP!H% | LOCK|?X | $350B | |||
| Merck & Co Inc
MRK
| LOCK|m<n@xN | LOCK|Jt@ | $335B | |||
| Novartis AG ADR
NVS
| LOCK|qyCdjQ&< | LOCK|#rz | $289B | |||
| AstraZeneca PLC
AZN
| LOCK|hWK%<H%C | LOCK|Tf | $243B | |||
| Amgen Inc
AMGN
| LOCK|^m>B?NGH | LOCK|ynd | $227B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|fVF?!! | LOCK|#% | $200B | |||
| Gilead Sciences Inc
GILD
| LOCK|?#FrSx | LOCK|%D | $172B |
United States